日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
China
Home / China / Health

Sino Biopharm targets 30 innovative products by 2027

By Zhou Wenting in Shanghai | chinadaily.com.cn | Updated: 2025-03-21 14:23
Share
Share - WeChat

Sino Biopharmaceutical Limited, or Sino Biopharm, expects to have approximately five innovative products approved in China each year, bringing the total of its innovative products to at least 30 by 2027, the company announced at a conference on Thursday, where it released its 2024 annual results.

Such continuous innovation efforts demonstrate the company's commitment to meeting patients' clinical needs and contributing to the Healthy China initiative, said Theresa Tse, chairwoman of Sino Biopharm.

The report showed that the Hong Kong-listed company's dedication to innovation has paid off, with its 2024 operating revenue and net profit both achieving double-digit growth. The company reported a total revenue of 28.87 billion yuan ($3.98 billion), representing a 10.2 percent year-on-year increase, while adjusted net profit attributable to shareholders reached 3.46 billion yuan, a 33.5 percent surge.

For the first time, the company also achieved over 10-billion-yuan revenue from its innovative products last year, reaching 12.06 billion yuan, a 21.9 percent year-on-year growth, which accounts for 41.8 percent of the company's total revenue.

"Our relentless focus on innovation over the past decade has led to the establishment of innovative research and development platforms for dual antibodies and ADC (antibody-drug conjugate) drugs among others, resulting in a steady stream of innovative products," said Tse.

The number of innovative products by Sino Biopharm increased from three in 2018 to 17 by the end of 2024, according to the report. Last year alone, the company saw four first-class innovative medicines approved for market, making it the pharmaceutical enterprise with the largest number of such approvals in the year.

Looking ahead, Sino Biopharm anticipates the launch of several blockbuster products for treatment of lung cancer, chronic obstructive pulmonary disease, breast cancer, and others within the next three years.

The company also said that it has strategically positioned itself in the realm of artificial intelligence through collaborations, investments and localized applications. It plans to intensify its investments in AI, expanding its application across R&D, production, sales and functional management to propel corporate development and lead industry innovation upgrades.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 一级国产黄色片 | 色网在线 | 91福利影院 | 在线欧美日韩 | 亚洲国产精品久久久久网站 | 久草资源总站 | 九九久久精品 | 六月色婷 | 日韩成人在线观看 | 一区二区三区欧美 | 亚洲成人二区 | 色狠狠成人综合色 | 日韩福利在线 | 国产精品日韩欧美在线第3页 | 精品亚洲国产成av人片传媒 | 欧美黄色第一页 | 九九99在线视频 | 91青青草视频在线观看 | 久久精彩免费视频 | 亚洲午夜精品aaa级久久久久 | 成人午夜动漫在线观看 | 久久久久久9 | 国产午夜高清 | 青草福利在线 | 挑战者联盟第一季免费观看完整版 | 午夜剧场操一操 | 欧美亚洲 尤物久久 综合精品 | 国产高清在线视频 | 国产精品久久久久久久免费大片 | 亚州va| 国产精品国产三级国产aⅴ中文 | 国产第113页 | 一级片一级片一级片一级片 | 国产欧美综合一区二区 | 成人精品视频一区二区三区尤物 | 久草福利站| 欧美日韩北条麻妃一区二区 | 欧美精品导航 | 在线成人免费视频 | 国内精品视频区在线2021 | 久久日韩精品中文字幕网 |